-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 23, Osaikang declared a new drug clinical application for the first class of new drug ASKC852 tablets, which was undertaken by CDE, which is a small molecule immunomodulatory drug.
Figure 1: The new drug that Osaikang has declared for clinical use this time
Source: CDE official website
Source: CDE official websiteAccording to data, ASKC852 is a new class 1 drug jointly developed by Aosaekang and Shanghai WuXi AppTec.
In the earlier pharmacodynamic experiment, ASKC852 single agent can have a significant inhibitory effect on tumors, and when combined with PD-L1 monoclonal antibody, it can also produce excellent synergistic effects, making PD-L1 monoclonal antibody anti-tumor effect Significantly improved.
Figure 2: New drugs declared and under review by Osaikang this year
Source: Meinenet MED2.
Source: Meinenet MED2.
It is reported that dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazole.
Table 1: Part of the latest developments of Aosaiken's Class 1 and Class 2 new drugs
Source: Meinenet MED2.
Source: Meinenet MED2.
Source: Minet database, CDE official website
Source: Minet database, CDE official websiteThe review data statistics are as of April 26, if there are any errors or omissions, please correct me.
The review data statistics are as of April 26, if there are any errors or omissions, please correct me.